上市筹备 · 2025-12-29

Valuation Methods for Pre-IPO Employee Share Option Schemes

The Hong Kong Stock Exchange’s (HKEX) 2024 enhancement to the Main Board Listing Rules (Chapter 17), effective 1 January 2025, has fundamentally altered the valuation landscape for pre-IPO Employee Share Option Schemes (ESOPs). The revised rules mandate that all issuers seeking a listing on the Main Board or GEM must provide a detailed, independent valuation of their ESOPs as part of the listing application (HKEX, 2024). This shift, codified in new guidance letters (HKEX-GL117-24), moves beyond the previous practice of a simple disclosure note. The Exchange now demands that the valuation methodology, key assumptions, and the fair value per option be explicitly justified, with the sponsor required to confirm the reasonableness of the approach. For CFOs and company secretaries, this is not a compliance box-ticking exercise. A poorly structured or inadequately supported ESOP valuation can now trigger substantive follow-up questions from the Listing Division, delaying the entire listing timetable. The stakes are high: a mispriced option scheme can distort the company’s financial statements under HKFRS 2 (Share-based Payment), create a material tax liability for the issuer and employees under Inland Revenue Ordinance (IRO) s.9(1)(a), and erode investor confidence in the IPO pricing. This article provides a rigorous, data-driven framework for selecting and defending the appropriate valuation method for pre-IPO ESOPs, with direct reference to the 2025 regulatory environment.

The Regulatory Mandate: Why Valuation Methodology is Now a Listing Criterion

The 2025 HKEX rule changes have elevated the ESOP valuation from a footnote in the accountants’ report to a core component of the listing application’s financial due diligence. The Exchange’s position is clear: the fair value of the employee share options directly impacts the issuer’s profit and loss statement and, consequently, its listing eligibility under the profit test (Main Board Rule 8.05(1)(a)) or the market capitalisation/revenue test (Main Board Rule 8.05(2)).

The Sponsor’s New Burden of Proof

Under the revised HKEX-GL117-24, the sponsor is now explicitly required to review and opine on the valuation methodology adopted for the ESOP. This is not a passive endorsement. The sponsor must document that the valuation approach is consistent with industry norms, the company’s specific circumstances (e.g., stage of development, volatility of its sector), and the principles of HKFRS 2. The key data point here is the requirement for the sponsor to confirm that the valuation does not result in a material misstatement of the issuer’s financial position. If the valuation is challenged, the sponsor faces direct regulatory scrutiny. This has led to a market-wide shift: sponsors are now actively engaging independent valuation firms earlier in the pre-IPO process, often 12-18 months before the expected A1 filing date, to ensure the methodology is locked in and defensible.

The Inland Revenue Ordinance (IRO) s.9(1)(a) Implications

A valuation that is too aggressive—either too high or too low—carries significant tax consequences under Hong Kong law. The IRO s.9(1)(a) treats the gain from the exercise of an employee share option as a taxable employment benefit. The taxable amount is the difference between the market value of the shares at the date of exercise and the exercise price. However, the valuation of the option at grant is critical for determining the company’s own tax deduction. Under IRO s.16(1), the employer can claim a deduction for the cost of providing the share option, which is the fair value of the option at the grant date. An undervalued option (relative to market reality) reduces the company’s tax deduction; an overvalued option inflates it, creating a risk of an IRD assessment and potential penalties. The HKEX’s 2025 rules effectively force issuers to adopt a valuation that is both commercially reasonable and tax-compliant, as the same valuation will be used for both listing disclosure and tax filing purposes.

The Three Primary Valuation Methods and Their Application

The choice of valuation method is not arbitrary. It must be driven by the specific characteristics of the issuer and the option scheme. The three primary methods accepted by the HKEX and consistent with HKFRS 2 are the Black-Scholes-Merton (BSM) model, the Binomial (or Lattice) model, and the Monte Carlo simulation. Each has distinct data requirements and is suited to different pre-IPO scenarios.

The Black-Scholes-Merton (BSM) Model: The Default for Simple, Non-Path-Dependent Options

The BSM model is the most widely used method for valuing plain-vanilla European-style options—options that can only be exercised at maturity. For a pre-IPO company, this is often the simplest and most defensible starting point, provided the option terms are standard (e.g., a fixed exercise price, a fixed vesting schedule, and no performance hurdles beyond service conditions). The model requires five inputs: the current share price (S), the exercise price (K), the time to expiry (T), the risk-free rate (r), and the expected volatility (σ). For a pre-IPO company, the current share price (S) is the most contentious input. It is typically derived from the latest pre-IPO funding round, or if no recent round exists, from an independent business valuation of the entire company (e.g., using a discounted cash flow or market multiple approach). The HKEX’s 2025 guidance explicitly states that the share price used for the ESOP valuation must be consistent with the price used in the most recent equity issuance to external investors (HKEX-GL117-24, para. 4.2). A discrepancy between the two will trigger a mandatory explanation from the sponsor.

The Binomial Model: Handling American-Style Features and Early Exercise

Many pre-IPO ESOPs are structured as American-style options, allowing employees to exercise at any point during the option’s life, often after a vesting period. The BSM model cannot accurately price this early exercise feature because it assumes a single exercise date. The Binomial (or Lattice) model addresses this by constructing a tree of possible share price movements over the option’s life, allowing the valuation to incorporate the optimal early exercise decision at each node. This is particularly relevant for pre-IPO companies with a high probability of an exit event (e.g., an IPO or trade sale) within the option’s life. For example, if an employee is granted options with a 10-year life but the company expects to list in 18 months, the Binomial model can more accurately reflect the likelihood that the employee will exercise the option immediately upon listing (when the shares become liquid) rather than holding it for the full 10 years. This model is more data-intensive than BSM, requiring an assumption about the company’s dividend yield and the employee’s exercise behaviour (often modelled as a multiple of the exercise price). The HKEX does not mandate a specific model, but the sponsor must justify why the chosen model is appropriate. For companies with complex vesting schedules or performance-based vesting conditions, the Binomial model is the standard.

Monte Carlo Simulation: The Standard for Performance-Based and Market-Condition Vesting

When the ESOP’s vesting is contingent on achieving specific performance conditions—such as a revenue target, an EBITDA hurdle, or a share price milestone—the BSM and Binomial models are inadequate. These conditions create path dependency: the option’s value depends not just on the final share price but on the entire trajectory of the company’s performance relative to the target. Monte Carlo simulation is the only method that can handle this complexity. It runs thousands of simulations of the company’s future financial performance and share price, generating a distribution of possible outcomes. The fair value of the option is the average of the values from each simulation where the vesting condition is met. This method is computationally intensive and requires a robust financial model of the company, including projections of revenue, costs, and capital structure. The HKEX’s 2024 consultation paper (HKEX-CP-2024-03) noted that Monte Carlo simulations are becoming more common for pre-IPO companies with aggressive growth targets, particularly in the biotech and tech sectors. The sponsor must ensure that the assumptions underlying the simulation are realistic and consistent with the company’s business plan disclosed in the prospectus.

The accuracy of any valuation model depends entirely on the quality of its inputs. For pre-IPO companies, three inputs are consistently the most scrutinised by the HKEX and the sponsor: expected volatility, the underlying share price, and the Discount for Lack of Marketability (DLOM).

Estimating Expected Volatility Without a Public Market

For a listed company, volatility is derived from historical share price data. For a pre-IPO company, this data does not exist. The standard approach, accepted by the HKEX, is to use the historical volatility of a peer group of comparable listed companies. The peer group must be carefully selected based on sector, business model, stage of development, and market capitalisation. For example, a pre-IPO biotech company developing a novel oncology drug would use the volatility of a basket of 10-15 listed biotech companies with similar pipeline stages and market caps, such as those on the Nasdaq or the HKEX’s own Biotech Chapter (Chapter 18C). The HKEX’s guidance (HKEX-GL117-24, para. 5.1) states that the peer group must be disclosed in the listing document, and any significant deviation from the peer group’s average volatility must be justified. A common error is using a peer group that is too broad (e.g., all technology companies) or too narrow (e.g., only direct competitors). The sponsor will typically require a sensitivity analysis showing how the option value changes with a +/- 10% change in the volatility assumption.

The share price used in the ESOP valuation must be the fair value of the company’s ordinary shares at the grant date. For a pre-IPO company, this is most reliably determined by the price per share in the most recent arm’s-length funding round involving external investors (e.g., a Series B or C round). If the ESOP grant occurs between funding rounds, the company must perform an independent valuation to determine the share price. The HKEX’s 2025 rules explicitly require the company to reconcile the ESOP valuation price with the price in the most recent funding round. If the ESOP price is lower (which is common, as options are often granted at a discount to the last round price to incentivise employees), the company must provide a clear rationale. Acceptable justifications include a decline in the company’s business prospects since the last round, a change in the market environment, or a specific discount for lack of control (the option holder does not have the same rights as a preferred shareholder). The sponsor will expect this reconciliation to be documented in a board paper or valuation report.

The Discount for Lack of Marketability (DLOM): Quantifying Illiquidity

Pre-IPO shares are, by definition, illiquid. An employee cannot sell the underlying shares until the company lists or is acquired. This illiquidity reduces the value of the option relative to a comparable option on a listed stock. The DLOM is the mechanism to capture this. The most common method for estimating the DLOM is the Restricted Stock Study (RSS) or the IPO Approach. The RSS compares the price of restricted shares (which cannot be traded for a period) to the price of freely traded shares in the same company. The IPO Approach compares the price of pre-IPO transactions to the IPO price. For Hong Kong pre-IPO companies, a DLOM in the range of 20% to 35% is typical, depending on the expected time to liquidity and the company’s specific risk profile. The HKEX does not prescribe a specific DLOM, but the sponsor must confirm that the DLOM applied is consistent with market practice and the company’s specific circumstances. A company with a clear, short-term IPO path (e.g., 6-12 months) would apply a lower DLOM than one with a longer or uncertain timeline. The valuation report must disclose the DLOM methodology and the specific percentage applied.

Practical Implementation: From Valuation to Prospectus Disclosure

The valuation is not an end in itself; it must be translated into precise, compliant disclosure in the prospectus and the accountants’ report. This section outlines the practical steps for CFOs and company secretaries.

Reconciling the Valuation with HKFRS 2 and the Accountants’ Report

The fair value determined by the valuation model directly feeds into the company’s profit and loss account as a share-based payment expense under HKFRS 2. The expense is recognised over the vesting period. The accountants’ report must disclose the total expense recognised, the number of options outstanding, and the weighted-average fair value per option. The HKEX’s 2025 rules require that the valuation methodology and key assumptions be disclosed in a note to the financial statements. A common pitfall is a mismatch between the valuation assumptions used for the ESOP and the assumptions used in the company’s business valuation (e.g., for the IPO price range). The sponsor will require a reconciliation to ensure consistency.

The Sponsor’s Comfort Letter and the Valuation Report

The sponsor will issue a comfort letter to the HKEX confirming that it has reviewed the ESOP valuation and that it is reasonable. This letter will reference a formal valuation report prepared by an independent valuer. The valuer must be a qualified professional (e.g., a member of the Hong Kong Institute of Certified Public Accountants or the Royal Institution of Chartered Surveyors). The valuation report must include: (1) a description of the option scheme, (2) the valuation methodology and justification, (3) a list of all key assumptions (volatility, share price, DLOM, risk-free rate), (4) the weighted-average fair value per option, and (5) a sensitivity analysis. The sponsor will typically require the valuer to provide a draft report at least two weeks before the A1 filing to allow time for review and potential revisions.

The Prospectus Disclosure: What the HKEX Expects

The prospectus must include a dedicated section on the ESOP, typically under “Share Option Scheme” or “Statutory and General Information.” The HKEX’s 2025 guidance (HKEX-GL117-24, para. 6.0) specifies the minimum disclosure: (1) the total number of options granted and outstanding, (2) the exercise price range, (3) the vesting schedule, (4) the fair value per option and total expense recognised, (5) the valuation methodology, and (6) the key assumptions. The Listing Division will review this section for consistency with the accountants’ report and the sponsor’s comfort letter. Any discrepancy—no matter how small—will result in a written query, delaying the listing process. The most common query relates to the justification for the DLOM. The company must be prepared to defend this number with specific reference to its liquidity timeline and market comparables.

Actionable Takeaways for the Pre-IPO Team

Engage an independent valuer 12-18 months before the planned A1 filing to establish the valuation methodology and key assumptions, ensuring alignment with the sponsor’s review timeline and avoiding last-minute revisions that could delay the listing.
Reconcile the ESOP valuation share price with the price in the most recent funding round in a formal board paper, documenting any discount and its justification, as this is the single most scrutinised input by the HKEX Listing Division under the 2025 rules.
Select the valuation model based on the option’s specific vesting conditions: use the BSM model for simple European-style options, the Binomial model for American-style options with early exercise features, and Monte Carlo simulation for options with performance-based or market-condition vesting hurdles.
Prepare a sensitivity analysis for the two most contested inputs—volatility and the DLOM—showing the impact of a +/- 10% change on the option’s fair value, and include this analysis in the valuation report provided to the sponsor.
Ensure the ESOP valuation assumptions are consistent with the business projections in the prospectus, particularly the revenue growth rate and the expected time to liquidity, as any inconsistency will be flagged by the HKEX as a material discrepancy requiring a formal explanation from the sponsor.